Cardiometabolic Comorbidities in COPD: Focus on Diabetes, GLP-1 Receptor Agonists, SGLT-2 Inhibitors and Antidiabetic Drugs. This evidence concerns the gene SLC5A2 and chronic obstructive pulmonary disease.